A new therapy may be on the horizon to improve skin outcomes in patients with cutaneous lupus erythematosus

Litifilimab—an investigational monoclonal antibody that targets blood dendritic cell antigen 2 (BDCA2) to reduce skin disease activity in cutaneous lupus erythematosus (CLE)—may soon be a new tool for clinicians. A new secondary analysis of this agent published in the British Journal of Dermatology found approximately one-third of patients with CLE achieved 70% or greater improvement in disease activity at 16 weeks. The new findings demonstrated that litifilimab improved skin-specific outcomes related to CLE, with greater efficacy consistently observed with litifilimab than with placebo across different Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A)-based outcomes and physician assessments. Currently, CLE has no approved targeted therapies. In Part B of the randomized, double-blind, placebo-controlled, Phase 2 LILAC Study, litifilimab demonstrated a dose-response relationship for percentage change in CLASI-A score from baseline to week 16.“We found that patients treated with litifilimab showed an early response to the drug with improvement of their CLE lesions relative to placebo. It was very interesting to realize that targeting plasmacytoid dendritic cells had such a profound effect on improving disease activity,” said study first author Dr. Victoria P. Werth, professor of Dermatology and Rheumatology at the University of Pennsylvania.The current study is run by a U.S.‐based team. Participants came from Argentina, Bulgaria, Colombia, Israel, Mexico, the Philippines, Poland, Serbia, South Korea, Taiwan, Thailand and the U.S. For this investigation, adult participants with baseline CLASI-A score ≥8 and histologically confirmed CLE, with/without systemic manifestations, received litifilimab 50 mg, 150 mg or 450 mg, or placebo subcutaneously every 4 weeks through week 16. Among the 132 participants (26, 25, 48 and 33 participants received litifilimab 50 mg, 150 mg, 450 mg and placebo, respectively), the mean respective baseline CLASI-A scores were 15.2, 18.4, 16.5 and 16.5. The researchers analyzed CLASI-20/50/70/90 responses (≥20%/50%/70%/90% decrease [improvement] from baseline in CLASI-A score). Shifts from baseline in skin condition were evaluated by the Physician's Global Assessment (PGA) of CLE and the Physician's Global Impression (PGI) of change in CLE. Greater proportions of litifilimab-treated participants achieved CLASI-20/50/70/90 responses (3.8%-72.1%) than placebo-treated participants (0%-43.8%) at week 16. Compared with placebo, more litifilimab-treated participants achieved 'clear' or 'almost clear' skin status at week 16.Litifilimab binds to BDCA2 on plasmacytoid dendritic cells, which helps stop the production of type I interferons and other inflammatory drivers of lupus skin lesions. The U.S. Food and Drug Administration (FDA) granted it Breakthrough Therapy Designation for CLE in January 2026. Standard treatments, such as topical steroids and antimalarials, often offer limited relief and carry significant side effects.At baseline, 106 participants (80.3%) had CLASI-A scores ≥10, and 26 participants (19.7%) had CLASI-A scores

A new therapy may be on the horizon to improve skin outcomes in patients with cutaneous lupus erythematosus

Register for free access or login.

Related Topics